Le Lézard
Classified in: Health
Subject: PER

Norbert Oppitz Joins Sobitm as New Senior Vice President, Specialty Care



STOCKHOLM, Oct. 6, 2017 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobitm) today announces that Norbert Oppitz has been appointed Senior Vice President for the newly established business area Specialty Care.

Norbert Oppitz brings considerable management experience from over 30 years in the Pharmaceutical and Healthcare Industry. Most recently he has been a member of the Executive Committee of BSN Medical in charge of Latin America. Beforehand, he was a member of the Executive Committee of Endo Pharmaceuticals where he was in charge of emerging markets. In previous capacities, he has led large organisations as Head of Latin America at Takeda/Nycomed as well as in country management roles at Roche Pharmaceuticals and Aventis Pharma.

"We are delighted that Norbert could join Sobi. Norbert is a true entrepreneur, and his experience will be instrumental in realising our ambitions to bring Sobi to the next level as we look for external growth opportunities for our Specialty Care business," says Guido Oelkers, President and CEO of Sobi.

Norbert Oppitz will head Sobi's Specialty Care organisation and work closely together with Corporate Development and the regional and country organisations. Norbert will be part of Sobi's Executive Leadership Team.

"I am excited to join Sobi ? a company with a strong, patient-centric profile and a great potential. I look forward to contributing to the future growth of the company by realising a strategy to build and develop a strong and vital Specialty Care business unit," says Norbert.

Norbert Oppitz joined Sobi on 2 October 2017.

About Sobitm

Sobitm is an international speciality healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of speciality and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2016, Sobi had total revenues of SEK 5.2 billion (USD 608 M) and approximately 760 employees. The share (STO:SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com

For more information please contact 

 Media relations

Investor relations

 Linda Holmström, Senior Communications Manager

Jörgen Winroth, Vice President, Head of Investor Relations

+46-70-873-40-95

+1-347-224-0819, +1-212-579-0506

 linda.holmstrom@sobi.com 

jorgen.winroth@sobi.com 

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/swedish-orphan-biovitrum-ab/r/norbert-oppitz-joins-sobi--as-new-senior-vice-president--specialty-care,c2361681

The following files are available for download:

SOURCE Swedish Orphan Biovitrum AB


These press releases may also interest you

at 08:33
Avalon GloboCare Corp. , a leading global developer of cell-based technologies, announced today that President and Chief Executive Officer David Jin, M.D., Ph.D. will chair a session entitled, "China's impact on the world of regenerative medicine,"...

at 08:04
2018 Report From J. Walter Thompson's Innovation Group MENA Forecasts 100 Trends, Depicting Region's Fast-Paced Evolution  J. Walter Thompson Middle East and Africa's Innovation Group released its sixth annual consumer trends report, covering the...

at 08:00
Braeburn Pharmaceuticals, Inc. (Braeburn) today announced that it has received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the new drug application (NDA) for CAM2038, an investigational buprenorphine...

at 03:00
PARK CITY, Utah and LOS ANGELES, Jan. 21, 2018 /PRNewswire-PRWeb/ -- SAFE SPACE Celebrates Thought Leaders, Influencers and Activists Working to Empower Women to Respect Themselves, Protect Themselves, Be Safe and Feel Safe. SAFE Movement announces...

20 jan 2018
Princeton Identity Inc., provider of the fastest, simplest and most secure biometric security system on the market, today announced the deployment of its Access500etm identity management kiosk module within the Dubai International Airport (DXB)....

20 jan 2018
Array BioPharma Inc. and Pierre Fabre today announced updated results from the 30 patient safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab,...




News published on 6 october 2017 at 02:28 and distributed by: